References
- Nieves, D. J. & Heininger, U. in Emerging Infections 10 Vol. 4 (eds Scheld, W., Hughes, J. & Whitley, R.) 311–339 (American Society of Microbiology, Washington, DC, 2016).
- AmirthalingamGSustained effectiveness of the maternal pertussis immunization program in England 3 years following introductionClin. Infect. Dis.201663 S236 S24310.1093/cid/ciw5595106626
- KleinNPBartlettJRowhani-RahbarAFiremanBBaxterRWaning protection after fifth dose of acellular pertussis vaccine in childrenN. Engl. J. Med.20123671012101910.1056/NEJMoa1200850
- SealeyKLBelcherTPrestonABordetella pertussis epidemiology and evolution in the light of pertussis resurgenceInfect. Genet. Evol.20164013614310.1016/j.meegid.2016.02.032
- LochtCLive pertussis vaccines: will they protect against carriage and spread of pertussis?Clin. Microbiol. Infect.201622S96S10210.1016/j.cmi.2016.05.029
- WarfelJMZimmermanLIMerkelTJAcellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate modelProc. Natl. Acad. Sci. USA.201411178779210.1073/pnas.1314688110
- PerssonCGPlasma exudation as a first line respiratory mucosal defenceClin. Exp. Allergy199121172410.1111/j.1365-2222.1991.tb00799.x
- LambrisJDRicklinDGeisbrechtBVComplement evasion by human pathogensNat. Rev. Microbiol2008613214210.1038/nrmicro18242814840
- DiavatopoulosDAEdwardsKMWhat is wrong with pertussis vaccine immunity? Why immunological memory to pertussis is failingCold Spring Harb. Perspect. Biol.20179a02955310.1101/cshperspect.a029553
- AaseAOpsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in NorwayClin. Vaccin. Immunol.20071485586210.1128/CVI.00081-07
- HellwigSMMRodriguezMEBerbersGAMvan de WinkelJGJMooiFRCrucial role of antibodies to pertactin in Bordetella pertussis immunityJ. Infect. Dis.200318873874210.1086/377283
- AaseAImmunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activityClin. Vaccin. Immunol.2011181269127410.1128/CVI.05067-11
- WeissAAMobberleyPSFernandezRCMinkCMCharacterization of human bactericidal antibodies to Bordetella pertussisInfect. Immun.1999671424143196476
- WeissAAAcellular pertussis vaccines and complement killing of Bordetella pertussisInfect. Immun.20157273465110.1128/IAI.72.12.7346-7351.2004
- BrummelmanJWilkMMHanWGHvan ElsCACMMillsKHGRoads to the development of improved pertussis vaccines paved by immunologyPathog. Dis.201573ftv06710.1093/femspd/ftv0674626578
- BarnesMGWeissAABrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 depositionInfect. Immun.2001693067307210.1128/IAI.69.5.3067-3072.200198261
- BerggårdKJohnssonEMooiFRLindahlGBordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutininInfect. Immun.19976536383643175517
- MarrNShahNRLeeRKimEJFernandezRCBordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistancePLoS ONE20116e2058510.1371/journal.pone.00205853114845
- NoofeliMBapC autotransporter protein is a virulence determinant of Bordetella pertussisMicrob. Pathog.20115116917710.1016/j.micpath.2011.04.004
- HovinghESAcquisition of C1 inhibitor by Bordetella pertussis virulence associated gene 8 results in C2 and C4 consumption away from the bacterial surfacePLOS Pathog.201713e100653110.1371/journal.ppat.10065315542704
- AmdahlHInteractions between Bordetella pertussis and the complement inhibitor factor HMol. Immunol.20114869770510.1016/j.molimm.2010.11.015
- Gröndahl-Yli-HannukselaKVianderMMertsolaJHeQIncreased risk of pertussis in adult patients with mannose-binding lectin deficiencyAPMIS201312131131510.1111/apm.12000
- SealeyKLGenomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolvingJ. Infect. Dis.201521229430110.1093/infdis/jiu665
- BartMJGlobal population structure and evolution of Bordetella pertussis and their relationship with vaccinationMBio20145e0107410.1128/mBio.01074-143994516
- BartMJComplete genome sequences of Bordetella pertussis isolates B1917 and B1920, representing two predominant global lineagesGenome Announc.201422310.1128/genomeA.01301-14
- McNeilLKRole of Factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal diseaseMicrobiol. Mol. Biol. Rev.20137723425210.1128/MMBR.00056-123668674
- BurnsDLMeadeBDMessionnierNEPertussis resurgence: perspectives from the Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in our knowledgeJ. Infect. Dis.2014209S32S3510.1093/infdis/jit491
- TartofSYWaning immunity to pertussis following 5 doses of DTaPPediatrics2013131e1047e105210.1542/peds.2012-1928
- MisegadesLKAssociation of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010JAMA2012308212610.1001/jama.2012.14939
- MooiFRVan Der MaasNATDe MelkerHEPertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coinEpidemiol. Infect.201414268569410.1017/S0950268813000071
- He, Q. & Mertsola, J. Factors contributing to pertussis resurgence. Future Microbiol. 10.2217/17460913.3.3.329 (2008).
- BarnesMGGrowth phase influences complement resistance of Bordetella pertussisInfect. Immun.20027040340610.1128/IAI.70.1.403-406.2002127634
- ThernAStenbergLDahlbäckBLindahlGIg-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement systemJ. Immunol.1995154375386
- HallströmTJarvaHRiesbeckKBlomAMInteraction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistanceJ. Immunol.20071786359636610.4049/jimmunol.178.10.6359
- JarvaHRamSVogelUBlomAMMeriSBinding of the complement inhibitor C4bp to serogroup B Neisseria meningitidisJ. Immunol.20051746299630710.4049/jimmunol.174.10.6299
- TsengYtNlpI facilitates deposition of C4bp on Escherichia coli by blocking classical complement-mediated killing, which results in high-level bacteremiaInfect. Immun.2012803669367810.1128/IAI.00320-123457581
- FernandezRCWeissAASerum resistance in bvg-regulated mutants of Bordetella pertussisFEMS Microbiol. Lett.1998163576310.1111/j.1574-6968.1998.tb13026.x
- MadicoGThe meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistanceJ. Immunol.200617750151010.4049/jimmunol.177.1.5012248442
- de GraafHInvestigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection modelBMJ Open20177e01859410.1136/bmjopen-2017-0185945652574
- van der ZeeAVernooijSPeetersMvan EmbdenJMooiFRDynamics of the population structure of Bordetella pertussis as measured by IS1002-associated RFLP: comparison of pre- and post-vaccination strains and global distributionMicrobiology19961423479348510.1099/13500872-142-12-3479
- FennellyNKBordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responsesInfect. Immun.2008761257126610.1128/IAI.00836-072258832
- LuuLDWCharacterisation of the Bordetella pertussis secretome under different mediaJ. Proteomics2017158435110.1016/j.jprot.2017.02.010
- RaevenRHMImmunoproteomic profiling of Bordetella pertussis outer membrane vesicle vaccine reveals broad and balanced humoral immunogenicityJ. Proteome Res.2015142929294210.1021/acs.jproteome.5b00258
- GouwDdeProteomics-identified Bvg-activated autotransporters protect against Bordetella pertussis in a mouse modelPLoS ONE20149e10501110.1371/journal.pone.01050114136822
- JongeriusISchuijtTJMooiFRPinelliEComplement evasion by Bordetella pertussis: implications for improving current vaccinesJ. Mol. Med. (Berl.)20159339540210.1007/s00109-015-1259-1
- PishkoEJBettingDJHutterCSHarvillETBordetella pertussis acquires resistance to complement-mediated killing in vivoInfect. Immun.2003714936494210.1128/IAI.71.9.4936-4942.2003187338
- BarnesMGWeissAAActivation of the complement cascade by Bordetella pertussisFEMS Microbiol. Lett.200322027127510.1016/S0378-1097(03)00132-0
- ImaizumiASuzukiYOnoSSatoHSatoYEffect of heptakis (2,6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussisInfect. Immun.19834111381143264618
- LittDJDetection of anti-pertussis toxin IgG in oral fluids for use in diagnosis and surveillance of Bordetella pertussis infection in children and young adultsJ. Med. Microbiol.2006551223122810.1099/jmm.0.46543-0
- BrookesCDevelopment of a large scale human complement source for use in bacterial immunoassaysJ. Immunol. Methods2013391394910.1016/j.jim.2013.02.007
- InatsukaCSPertactin is required for Bordetella species to resist neutrophil-mediated clearanceInfect. Immun.2010782901290910.1128/IAI.00188-102897405